Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CERo Therapeutics Holdings ( (CERO) ) just unveiled an announcement.
On June 11, 2025, CERo Therapeutics Holdings received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for its common stock. However, by July 7, 2025, the company regained compliance, ensuring its continued listing and trading on the Nasdaq Capital Market, thus averting potential delisting and maintaining its market presence.
The most recent analyst rating on (CERO) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
CERo Therapeutics Holdings, Inc. operates in the biotechnology industry, focusing on developing innovative therapeutic solutions. The company is primarily engaged in the research and development of novel treatments for various diseases, with a market focus on advancing healthcare through cutting-edge biotechnological applications.
Average Trading Volume: 1,202,432
Technical Sentiment Signal: Sell
Current Market Cap: $4.6M
Find detailed analytics on CERO stock on TipRanks’ Stock Analysis page.